Moreover, currently, as the next generation of immune checkpoint therapy in cancer, LAG-3 has been confirmed as an important candidate target, for example, the clinical trials NCT00732082, NCT00349934, NCT02614833, NCT01968109 and NCT02460224, have shown that LAG-3 blockade can not only improve the antitumor immune responses but also can potentiate other forms of immunotherapy [33]. The gene discussed is LAG3; the disease is cancer.